Fulcrum Gains Momentum After Agios Trial Miss
Fulcrum Therapeutics rises as Agios’ RISE UP trial falls short. Analysts say results reduce competition in sickle cell disease and strengthen Fulcrum’s position ahead of new PIONEER data.
/ 9 items
#AGIO↓
Agios Mitapivat Trial Shows Promise but Misses Key Goals
Agios Pharmaceuticals reports mixed Phase 3 results for mitapivat in sickle cell disease, meeting some endpoints while missing key pain crisis reduction goals.
FDA Review for Agios' PYRUKYND in Thalassemia Extended to December 2025
The FDA extended PYRUKYND's review for thalassemia by 3 months to Dec 7, 2025, after Agios submitted a plan (REMS) to manage liver injury risk. This oral medicine aims to treat adult alpha- or beta-thalassemia.